MESSAGE FROM DAVID PIDDUCK, PRESIDENT AND CEO: ADHD AWARENESS MONTH
According to the Centre for ADHD Awareness, Canada (CADDAC), Attention Deficit Hyperactivity Disorder (ADHD) is the most prevalent neurodevelopmental disorder observed in childhood, occurring in one-in-20 school-aged children. It also occurs globally in four per cent of adults – yet people living with ADHD continue to experience stigma due to a general misunderstanding of the condition, and ADHD patient groups report that access to diagnosis and treatment remain an obstacle to many. Despite these challenges, recent years have brought encouraging improvements in public understanding and awareness of the condition, and many people with ADHD are living highly productive lives while managing their condition.
At Purdue Pharma (Canada) we are passionate about improving the lives of people living with ADHD. For more than 10 years in Canada, the company has conducted research and development in the field of ADHD.
To hallmark ADHD Awareness Month this October, the company has launched a Canada-wide survey to explore attitudes and knowledge related to the condition. Looking at the results, it is encouraging to see that awareness of ADHD is growing, with 83 per cent of Canadian respondents knowing that adults, not just children, can be diagnosed with the condition.[i]
However, there is still a long way to go. For example, our poll found that one quarter of Canadians surveyed were not sure whether people diagnosed with ADHD eventually outgrow the condition. In fact, 60 per cent of children remain affected by the symptoms of ADHD well into adulthood.
Of notable concern regarding stigma, almost half (44 per cent) of Canadians mistakenly identified ADHD as a mental illness, when in reality it is a neurodevelopmental disorder.
By sharing this information we hope to engage Canadians in an ongoing conversation to help minimize the stigma and misperceptions of ADHD; shed light on the importance of a timely, accurate medical diagnosis; and support a multidisciplinary approach to managing the condition. Further, we are committed to educating health care professionals on appropriate prescribing of all ADHD treatments and overall management of the condition.
We at Purdue Pharma (Canada) are proud to be a part of the vibrant and thriving ADHD community, and look forward to continuing to help people with ADHD live healthy and productive lives.
[i] The Purdue Pharma (Canada) 2017 ADHD Awareness Month poll was conducted via national online survey of n=1362 Canadians between June 23 –July 4, 2017 (an associated margin of error for a randomly selected sample of this size would be ±2.7%, 19 times out of 20).